Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.39

€1.39

1.010%
0.014
1.010%
€2.69
 
27.02.24 / Tradegate WKN: A2PLTK / Symbol: PSNL / Name: Personalis / Stock / Biotechnology & Medical Research / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Personalis

sharewise wants to provide you with the best news and tools for Personalis, so we directly link to the best financial data sources.

News

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock options

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive

Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023.

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives


Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff. By consolidating

Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing


Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic

Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the launch of the Early Access Program for NeXT Personal Dx, a tumor-informed, whole

Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology


Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a

Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical